Literature DB >> 26224888

Hypofractionated electron-beam radiation therapy for keloids: retrospective study of 568 cases with 834 lesions.

Jie Shen1, Xin Lian1, Yuliang Sun1, Xiaojun Wang2, Ke Hu1, Xiaorong Hou1, Shuai Sun1, Junfang Yan1, Lang Yu1, Xiansong Sun1, Wenbo Li1, Xinhai Wang1, Qiu Guan1, Tingtian Pang1, Fuquan Zhang3.   

Abstract

We aimed to analyze the outcomes of hypofractionated high-energy electron beam radiotherapy for the treatment of keloids. From February 1998 to January 2012, 568 patients with a total of 834 keloids underwent radiotherapy: 826 lesions with postoperative radiotherapy, and 36 with skin-grafting. Lesion size was >5 cm in 335 keloids. An electron-beam of 6 or 7 MeV was used, with a total dose of 18 Gy (two fractions with a 1-week interval) covering the lesion with a 1-cm margin. The time between surgery and radiotherapy was 24-48 h. Skin-grafted patients underwent radiotherapy 10-15 days after the operation. The median follow-up was 40 months (range: 12-160 months). The local control rate was 88.25% (736/834). The relapse rate was 9.59% (80/834), and the time to relapse was 6-28 months (median: 12 months). Univariate analyses showed that gender, age, keloid size, keloid site, skin grafting, and operation-to-irradiation interval influenced the local control rate. Multivariate analysis showed that the relapse rate was correlated with gender (P = 0.048), age (P < 0.01), operation-to-irradiation interval (P < 0.01), keloid site (P < 0.01), surgical method (P = 0.04) and keloid size (P < 0.02). Adverse effects were observed in 9.83% (82/834). No radiation-induced cancers were observed. Hypofractionated high-energy electron beam radiotherapy for keloids yielded excellent outcomes, especially in cases without skin grafting. Early postoperative radiotherapy with limited hypofractionation could be a good choice for keloid treatment.
© The Author 2015. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology.

Entities:  

Keywords:  assessment; electron beam; keloids; prognosis; radiotherapy

Mesh:

Year:  2015        PMID: 26224888      PMCID: PMC4577000          DOI: 10.1093/jrr/rrv031

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


INTRODUCTION

A keloid is a benign disease characterized by a variable growth of dense fibrous tissue due to an abnormal healing response to a cutaneous injury, sometimes beyond the original borders of the wound. It may cause itching, tenderness and pain, and may be disfiguring. Therefore, treatment is often necessary and may include corticosteroids, surgery, cryosurgery, laser therapy, chemotherapy and/or radiotherapy. The recurrence rate after simple excision is 45–100% [1]. The results from studies on postoperative radiotherapy are controversial, but there is strong evidence suggesting that postoperative radiotherapy is commonly used to suppress the overgrowth of scar tissue [2]. Indeed, the recurrence rate after radiation therapy is ∼20% [3]. A randomized trial of surgery and immediate radiotherapy vs surgery and cryotherapy and intralesional steroid injection have shown that patients undergoing surgery and adjuvant irradiation had less recurrence than cryotherapy and intralesional steroid injection, and had a better safety profile [4]. A study showed that high-energy electron radiotherapy could provide a better dose distribution compared with the use of kilovoltage X-rays for controlling keloids [5]. Furthermore, Flickinger et al. [6] have suggested that radiotherapy with a limited number of fractions and with a high dose per fraction is the best strategy for the postoperative treatment of keloids. However, the total radiation dose and the number of fractions are still controversial. In the present study, we assessed our cases of keloids treated with postoperative radiotherapy, and analyzed long-term control under a range of conditions, including keloid size, keloid site, surgical methods, and time interval between surgery and radiotherapy. In addition, we assessed treatment response and adverse effects.

MATERIALS AND METHODS

Patients

This retrospective study was conducted at the Department of Orthopedics and the Department of Radiation Oncology, Peking Union Medical College Hospital in Beijing. From February 1998 to January 2012, 834 keloids in 568 patients were treated with radiotherapy. All patients with keloids treated using surgery and radiotherapy were included, and this is the standard treatment in our center. Patients with a history of previous treatments for keloids were excluded. For patients who underwent multiple lines of treatment, only the first treatment was considered.

Treatment

The external beam was administered with 6 or 7 MeV electrons. In our center, two factors are considered crucial for treatment success, and they are systematically verified at each treatment. First, the scar in a specific radiation field should remain flat and its position confirmed by the clinician. Second, 0.5 cm of wax is used to improve the surface dose. The radiation field includes the entire scar or the entire postoperative scar (including structure/puncture hole), with a margin of 1 cm around the lesion. Non-target areas are shielded using a 0.8-cm customized lead sheet. A total dose of 18 Gy in two fractions a week apart was prescribed. The required monitor unit and treatment times were calculated manually.

Evaluation of treatment response and adverse effects

The evaluation standards were proposed by Enhamre and Hammar [7] and by Veen and Kal [8]. The responses to treatment were classified into four levels: Level I (Good), no visible scar or small scar in the plane of the skin, no complaints, and no recurrence during follow-up; Level II (Improved), no itching or other complaints, visible scar partly elevated by no more than 1 mm above the plane of the skin, slight dehiscence, and no recurrence during follow-up; Level III (Invalid), scar remained and was accompanied by swelling and itching symptoms after treatment, within 3 months; and Level IV (Relapse), treatment was effective for 3 months, but scar became elevated above the plane of the skin, or scar dehiscence and itching and erythema symptoms appeared again, all after 3 months. Patients achieving Levels I and II were defined as well controlled. The initial treatment response was evaluated in all 568 patients (834 lesions) at the first follow-up examination (1–3 months after the end of radiotherapy). In our center, the follow-up policy for keloid patients with radiotherapy consists of a 3-month observation. The end of follow-up was in June 2013, and the median follow-up was 40 (range 12–160) months. Acute radiotherapy-related complications were: skin ulceration within the radiation field, unhealed wound, and/or grafted skin necrosis after operation. Chronic adverse effects included skin hyperpigmentation and/or telangiectasia with depigmentation (occurring within a year after treatment). Some severe skin hyperpigmentation affected cosmetic appearance.

Statistical analysis

The long-term recurrence rate and radiotherapy-related adverse effect rate were analyzed using the Kaplan–Meier method and the log-rank test. Multivariate analysis was performed, and the Cox proportional hazard model was used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs). All statistical analyses were performed using the R software, version 3.0.1 GUI 1.61 Snow Leopard builds (6492). P-values <0.05 were considered statistically significant.

RESULTS

Characteristics of the patients and lesions

Patient and lesion characteristics are summarized in Tables 1 and 2. There were 103 men and 465 women, aged between 5 and 80 years, most of them being between 21 and 35 years (median age of 29 years). Of the lesions, 331 were in a site with high stretch tension (such as the chest wall, back, shoulder, or lower limbs), and 503 were in a site with low stretch tension (such as ear lobe, face, neck, abdomen or upper limbs). Of the 568 patients with 834 lesions, 8 preoperative radiotherapy patients (each patient with one lesion) received the first fraction before surgery, and the second fraction within 48 h after surgery. So, of the 834 lesions, 690 were treated with postoperative radiotherapy within 48 h of surgery, and 144 lesions were treated >48 h after surgery. Twenty-two patients (36 of the 834 lesions) received radiotherapy 10–15 days after skin graft surgery, to allow for grafted skin-flap survival.
Table 1.

Demographics of 568 patients

Number of patients (%)
Gender
 Males103 (18.1)
 Females465 (81.9)
Age (years)
 <102 (0.4)
 10–1956 (9.9)
 20–29228 (40.1)
 30–39123 (21.7)
 40–4971 (12.5)
 50–5949 (8.6)
 60–7023 (4.0)
 >7016 (2.8)
Median (range)29 (5–80)
Keloid lesions
 1385 (67.6)
 2135 (23.8)
 329 (5.1)
 414 (2.5)
 52 (0.4)
 61 (0.2)
 71 (0.2)
 81 (0.2)
Median (range)1 (1–8)
Total568
Table 2.

Characteristics of 834 lesions

Number of lesions (%)
Longest axis (cm)
 ≤5499 (59.8)
 >5335 (40.2)
Site
With high stretch tension
 Chest wall206 (24.7)
 Back36 (4.3)
 Shoulder56 (6.7)
 Lower limbs33 (4.0)
With low stretch tension
 Ear lobe239 (28.6)
 Face19 (2.3)
 Neck57 (6.8)
 Abdomen120 (14.4)
 Upper limbs68 (8.2)
Treatment method
 Radiotherapy before surgery8 (1.0)
 Radiotherapy after surgery826 (99.0)
Surgery method
 With skin grafting36 (4.3)
 Without skin grafting798 (95.7)
Interval time from surgery to radiotherapy (h)
 ≤24641 (76.8)
 ≤4849 (5.9)
 >48144 (17.3)
Demographics of 568 patients Characteristics of 834 lesions

Treatment results

The results of treatments are presented in Table 3. Most lesions (88.25%, 736/834) achieved Level I (539/834) or Level II (197/834) responses. Level III and IV responses occurred in 2.16% (18/834) and 9.59% (80/834) of lesions, respectively. The median time to recurrence was 12 (range 6–28) months.
Table 3.

Response to treatment according to various factors

FactorCategory (n)Result of treatment response (n)
Well controlled (%)P-value
Level ILevel IILevel IIILevel IV
Longest axis (cm)≤5 (499)3599563990.98<0.01
>5 (335)180102124184.18
SiteEar lobe (239)195365396.65<0.01
Chest wall (206)1115953182.52
Abdomen (120)76350992.50
Upper limbs (68)361611576.47
Neck (57)31214191.23
Shoulder (56)271311571.43
Back (36)2390488.89
Lower limbs (33)2461290.91
Face (19)1171094.74
Surgery methodWith skin grafting (36)1883772.22<0.01
Without skin grafting (798)521189157388.97
Interval time from surgery to radiotherapy (h)≤24 (641)42616883992.67<0.01
≤48 (49)26116675.51
>48 (144)852043572.92
Response to treatment according to various factors Among the 18 lesions with a Level III response after treatment, 4 had received skin grafts, 12 were large primary keloids (>5 cm), and 4 received radiotherapy more than 48 h after surgery. Furthermore, 7 of these lesions were in an area with high stretch tension. Among the 80 lesions with a Level IV response after treatment, 7 had received skin grafts, 41 were large primary keloids (>5 cm) and 35 received radiotherapy more than 48 h after surgery. In addition, 52 of these lesions were in an area with high stretch tension. Figure 1 and Table 4 show the results from the univariate analyses. Gender, age, lesion size, lesion site, skin grafting, and time interval between surgery and irradiation were significant factors affecting response to treatment. Regarding gender, the control rate was 79.18% in males (median control time of 40 months) and 91.93% in females (median control time of 44 months). With respect to age, the control rate was 87.19% in those ≤29 years (median control time of 41 months) and 91.52% in those >29 years (median control time of 51 months). With respect to lesion size, the control rate was 92.02% in lesions ≤5 cm (median control time of 42 months), compared with 85.81% in large lesions (>5 cm, median control time of 38 months). With respect to lesion site, the control rate was 93.68% in low-tension stretch sites (median control time of 50 months), compared with 83.24% in high-stretch tension sites (median control time of 36 months). With respect to the surgical approach, the control rate of surgery with skin grafting was 76.32% (median control time of 34 months), compared with 90.09% with surgery alone (median control time of 48 months). With respect to the time interval between surgery and radiotherapy, the control rate was 91.48% when the time interval was ≤24 h (median control time of 51 months), compared with 86.04% for >24 h and ≤48 h (median control time of 41 months), and with 81.25% for >48 h (median control time of 36 months).
Figure 1.

Univariate analyses of control rate. (A) Gender, female vs male. (B) Age, ≤29 vs >29 years. (C) Keloid size, ≤5 cm vs >5 cm. (D) Keloid site, low stretch tension vs high stretch tension. (E) Surgical approach, without skin grafting vs with skin grafting. (F) Time interval between surgery and radiotherapy, ≤24 h vs 48 h vs >48 h.

Table 4.

Long-term control of 834 lesions

FactorCategoryControl rate (%)Univariate analysis
Multivariate analysis
Median control time and Confidence Interval (months)P-valueHazard ratio and Confidence IntervalP-value
GenderMale79.1840 (38.78–44.47)<0.0110.048
Female91.9344 (36.92–48.88)0.63 (0.41–0.99)
Age≤29 years87.1941 (38.51–43.32)<0.011
>29 years91.5251 (48.16–54.73)0.42 (0.27–0.65)<0.01
Longest axis≤5cm92.0242 (38.13–48.81)0.011<0.01
>5cm85.8138 (34.23–41.61)2.05 (1.34–3.15)
SiteWith low stretch tension93.6850 (47.91–56.49)<0.011<0.01
With high stretch tension83.2436 (34.27–38.78)1.91 (1.26–2.89)
Surgery methodWith skin grafting76.3234 (32.71–36.27)<0.0110.04
Without skin grafting90.0948 (42.49–51.05)0.51 (0.25–0.97)
Interval time from surgery to radiotherapy (h)≤2491.4851 (48.96–59.69)<0.0110.017
≤4886.0441 (36.42–47.56)1.52 (1.33–1.82)
>4881.2536 (34.07–37.22)1.77 (1.32–1.89)
Long-term control of 834 lesions Univariate analyses of control rate. (A) Gender, female vs male. (B) Age, ≤29 vs >29 years. (C) Keloid size, ≤5 cm vs >5 cm. (D) Keloid site, low stretch tension vs high stretch tension. (E) Surgical approach, without skin grafting vs with skin grafting. (F) Time interval between surgery and radiotherapy, ≤24 h vs 48 h vs >48 h. Table 4 presents the multivariate analysis. Gender, age, lesion size, lesion site, skin grafting, and time interval between surgery and irradiation remained statistically significant. Females displayed a decreased relapse rate compared with male (HR = 0.63, 95% CI: 0.41–0.99, P = 0.048). Patients ages >29 years displayed a decreased relapse rate compared with those ≤29 years (HR = 0.42, 95% CI: 0.27–0.65, P < 0.01). Keloids >5 cm displayed an increased relapse rate compared with keloids ≤5 cm (HR = 2.05, 95% CI: 1.34–3.15, P < 0.01). Keloids in sites with high stretch tension displayed an increased relapse rate compared with keloids in sites with low stretch tension (HR = 1.91, 95% CI: 1.26–2.89, P < 0.01). Surgery without skin grafting displayed a decreased relapse rate compared with surgery with skin grafting (HR = 0.51, 95% CI: 0.25–0.97, P < 0.01). Time intervals of >24 h but ≤48 h between surgery and radiotherapy (HR = 1.52, 95% CI: 1.33–1.82, P < 0.02) and of >48 h (HR = 1.77, 95% CI: 1.32–1.89, P < 0.02) showed an increased relapse rate compared with the time interval of ≤24 h. No acute radiotherapy-related adverse effect was observed. The chronic adverse effect rate was 9.83% (82/834). Pigmentation was the most common adverse effect, and it occurred during the year after radiotherapy. No cases of treatment-related cancers occurred during follow-up.

DISCUSSION

Keloids are benign lesions caused by abnormal wound responses in predisposed individuals, and are an excessive connective tissue response to trauma, inflammation, surgery or burns [9]. In keloids, collagen synthesis is ∼20 times greater than in normal unscarred skin, and three times greater than in hypertrophic scars [10]. This collagen overproduction can be attributed to a stronger proliferating activity of keloid fibroblasts [11]. In vitro, inhibition of proliferation of fibroblasts by repeated irradiations with cumulative doses of up to 10 Gy yielded similar effects to single irradiations [12]. The results of the present study suggest that the treatment of keloids with surgery and immediate hypofractionated high-dose radiotherapy was efficient and safe, especially for keloids in the face and neck. In addition, no radiation-associated severe early or late toxicity was observed during follow-up, and no radiation-induced secondary malignancy was observed during follow-up. It has been demonstrated that keloids can be prevented from growing using immediate postsurgical radiotherapy [13, 14]. In a review of studies about postoperative keloid radiotherapy, Kal and Veen [15] recommended a relatively high biological effective dose (BED) of 30–40 Gy. In the present study, we used 18 Gy/2 fr, which corresponds to a dose of 28.8–34.2 Gy, and we obtained a good control rate. In addition, the incidence of adverse reactions was very low. A systematic review by Flickinger et al. [6] of all studies reporting results about postoperative external beam radiotherapy for keloids concluded that deeper-penetrating radiotherapy with an electron beam or 60Co led to significantly lower recurrence rates after keloid resection compared with other radiotherapy techniques. In the present study, our results confirmed that high BED should be used in postoperative radiation using a linear particle accelerator (LINAC) electron beam. Disorganized collagen leading to a keloid is laid down by fibroblasts that have migrated into the wound 2–10 days after injury [16]. Therefore, early intervention with radiotherapy should be the best timing for the treatment of keloids. Studies have reported that the threshold dose should be 12–14 Gy in a single fraction for reliable control by X-rays in a postoperative setting, and that radiotherapy should be given immediately after excision [7, 17–19]. Enhamre and Hammar [7] observed no association between treatment outcomes and the time interval between excision and radiation. Sakamoto et al. [20] stated that the time interval from operation did not affect the local control and adverse effects after radiotherapy. In the present study, the time interval after surgery significantly affected treatment efficacy. Indeed, patients who received radiotherapy within two days after operation had a better prognosis than patients who received radiotherapy more than two days after surgery. Therefore, we recommend that undergoing radiotherapy within 24 h after surgery may be the best timing for the control of keloids. However, differences in treatment regimens could have introduced some confusion, resulting in conflicting results. Indeed, Sakamoto et al. used regimens ranging from 16 Gy/8 fr to 40 Gy/8 fr, whereas we used 18 Gy/2 fr. Further randomized prospective trials should be designed to address this issue. According to Flickinger et al. [6], BEDs of the various irradiation regimens were recalculated using the linear–quadratic (LQ) method. The dose–response function for keloids has a low α/β ratio, similar to that of late radiation injury reactions. Thus, short treatment regimens with few fractions and high doses should work well and have similar adverse effects compared with regimens with more fractions. Kal et al. [21] performed a meta-analysis of postoperative scar radiotherapy using 27 published studies, and the various dose fractionations were converted into BED using the LQ method. The resulting dose–effect relationship suggested that for a BED of <30 Gy, the radiation dose was suboptimal. For a BED of ≥30 Gy, the incidence of keloid recurrence was <10%. In the present study, the dose fractionation was 18 Gy in two fractions, with a BED equivalent of 34.2 Gy. Therefore, it was sufficient for keloid control with a low incidence of adverse effects. In previous studies, the recurrence rate in patients who received immediate postsurgical radiotherapy was dependent upon higher skin stretch, but not upon lesion size [13, 14]. Ogawa et al. [3] reported that keloids in high-tension sites (such as the chest wall, shoulder and supraclavicular) should receive higher doses than keloids in low-tension sites (such as the earlobes, neck and upper extremities). Results of the present study showed that keloids occurring in the neck, face and torso displayed better responses than those in the limbs and shoulders. However, these results suggest that lesion size also influenced the recurrence rate. Therefore, the radiation dose distribution cannot be perfect, and the relapse still occurred. On the other hand, small keloids in low-tension areas, such as on the head, face and neck, achieved good outcomes. Keloids can be treated surgically, either by resection or by radical mass reduction [22]. In a study by Ogawa et al. [23], patients with huge keloids who were treated using flaps and postoperative radiotherapy displayed an uneventful follow-up, and keloid recurrence was not observed. In the present study, patients who underwent radiotherapy after skin grafting had a higher relapse rate than those without skin grafting. We propose two reasons for the poorer control rate. Keloids with skin grafting surgery not only suffered from a long time interval between excision and radiation, but also suffered from a larger wound surface size. The recurrence rate in our study was 11.75% (98/834). Furthermore, in this study, most of these lesions were on the trunk and limbs. However, skin grafting is sometimes used to treat keloids, and we think that determining how these patients react to radiation therapy is important. We have included a Supplemental Table 1 (below) that shows the same analyses but without including the 36 lesions treated with skin grafting. The results are similar to those obtained for the whole study, so postoperative radiotherapy is still recommended for skin graft patients. Our study examined early and late radiotherapy toxicities. The most frequent early toxicity was skin erythema (in more than half the lesions), as reported by Speranza et al. [24]. Bischof et al. [13] achieved good to excellent self-satisfaction ratings (62%) with radiation therapy, reporting that subjective assessments did not always fully correlate with clinical examination or incidence of recurrence. Kim and Lee [25] presented 26 postpartum patients with confirmed keloids resulting from previous Cesarean sections: most patients (96%) were satisfied with treatment outcomes. In the present study, despite experiencing some degrees of local recurrence, most subjects remained satisfied with their treatment results. For the late toxicities, Speranza et al. [24] reported that the rate of telangiectasia occurrence was 27%. Ogawa et al. [3] reported that the rate of late adverse effects was 45.6% 6 months after treatment. The present study showed that the most common treatment-related adverse effect was pigmentation occurring during the year following radiotherapy. No radiotherapy-related secondary malignancies occurred in patients with keloids after long-term follow-up, as previously reported [20, 26]. The present study is not without limitations. Despite the high number of patients, all patients were from the same center, which could introduce center bias. In addition, the follow-up duration was sufficient for observing the recurrence of keloids, but might be not long enough to observe some late toxicities, especially secondary malignancies. This cohort of patients will be followed up, and an update will be presented in a few years. Finally, there was a discrepancy in the gender distribution, and we had no data that could explain the reason for this discrepancy. In conclusion, the results of the present study indicated that surgery and immediate postoperative (within 48 h) radiotherapy (with 6–7 MeV LINAC electron beam) was an effective and relatively safe choice for the treatment of keloids. More economical and convenient short treatment regimens with high doses and hypofractionation (18 Gy in 2 fractions with a 1-week interval) worked well. Skin-grafted keloids have higher recurrence rates than those without skin grafting. Stretch tension should be taken into account when planning treatment.
  26 in total

Review 1.  Biologically effective doses of postoperative radiotherapy in the prevention of keloids. Dose-effect relationship.

Authors:  Henk B Kal; Ronald E Veen
Journal:  Strahlenther Onkol       Date:  2005-11       Impact factor: 3.621

2.  Postoperative high-dose-rate brachytherapy in the prevention of keloids.

Authors:  Ronald E Veen; Henk B Kal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-15       Impact factor: 7.038

3.  Dose-response relationship and dose optimization in radiotherapy of postoperative keloids.

Authors:  Takashi Sakamoto; Natsuo Oya; Keiko Shibuya; Yasushi Nagata; Masahiro Hiraoka
Journal:  Radiother Oncol       Date:  2009-02-07       Impact factor: 6.280

Review 4.  Dose-effect relationships for recurrence of keloid and pterygium after surgery and radiotherapy.

Authors:  Henk B Kal; Ronald E Veen; Ina M Jürgenliemk-Schulz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-01       Impact factor: 7.038

5.  Treatment of keloids with excision and postoperative X-ray irradiation.

Authors:  A Enhamre; H Hammar
Journal:  Dermatologica       Date:  1983

6.  The most current algorithms for the treatment and prevention of hypertrophic scars and keloids.

Authors:  Rei Ogawa
Journal:  Plast Reconstr Surg       Date:  2010-02       Impact factor: 4.730

7.  Surgical excision and immediate postoperative radiotherapy versus cryotherapy and intralesional steroids in the management of keloids: a prospective clinical trial.

Authors:  Maryam Emad; Shapour Omidvari; Ladan Dastgheib; Afshin Mortazavi; Haleh Ghaem
Journal:  Med Princ Pract       Date:  2010-07-14       Impact factor: 1.927

8.  Radiotherapy in the management of keloids. Clinical experience with electron beam irradiation and comparison with X-ray therapy.

Authors:  Mohammad Maarouf; Ursula Schleicher; Axel Schmachtenberg; Jürgen Ammon
Journal:  Strahlenther Onkol       Date:  2002-06       Impact factor: 3.621

9.  Therapeutic results and safety of postoperative radiotherapy for keloid after repeated Cesarean section in immediate postpartum period.

Authors:  Juree Kim; Sang Hoon Lee
Journal:  Radiat Oncol J       Date:  2012-06-30

10.  Proliferating activity of dermal fibroblasts in keloids and hypertrophic scars.

Authors:  H Nakaoka; S Miyauchi; Y Miki
Journal:  Acta Derm Venereol       Date:  1995-03       Impact factor: 4.437

View more
  19 in total

1.  Consensus Guidelines on the Use of Superficial Radiation Therapy for Treating Nonmelanoma Skin Cancers and Keloids.

Authors:  Mark S Nestor; Brian Berman; David Goldberg; Armand B Cognetta; Michael Gold; William Roth; Clay J Cockerell; Brad Glick
Journal:  J Clin Aesthet Dermatol       Date:  2019-02-01

Review 2.  RADIATION THERAPY for the Adjunctive Treatment of Surgically Excised Keloids: A Review.

Authors:  Nikoo Cheraghi; Armand Cognetta; David Goldberg
Journal:  J Clin Aesthet Dermatol       Date:  2017-08-01

Review 3.  Adjuvant Radiotherapy for Keloids.

Authors:  Wenfang Dong; Bin Qiu; Fei Fan
Journal:  Aesthetic Plast Surg       Date:  2021-08-20       Impact factor: 2.326

4.  Hyperbaric oxygen therapy relieved pruritus and pain of keloid patients.

Authors:  Wen-Bo Li; Shu Liu; Ming-Zi Zhang; Hao Liu; Xin-Hang Dong; Yan Hao; Yi-Fang Liu; You-Bin Wang
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

5.  Surface brachytherapy in the treatment of keloid scars in Mexico.

Authors:  Yicel Bautista Hernandez; Michelle Aline Villavicencio Queijero; Abril Antonia Quezada Bautista; Azcary Vazquez Tinajero
Journal:  Rep Pract Oncol Radiother       Date:  2019-12-24

6.  Risk factors of recurrence after postoperative electron beam radiation therapy for keloid: Comparison of long-term local control rate.

Authors:  Hitoshi Maemoto; Shiro Iraha; Ken Arashiro; Kousei Ishigami; Fumikiyo Ganaha; Sadayuki Murayama
Journal:  Rep Pract Oncol Radiother       Date:  2020-05-19

7.  Postoperative radiotherapy in the management of keloids.

Authors:  Claudia C Carvajal; Carla M Ibarra; Douglas L Arbulo; Moisés N Russo; Claudio P Solé
Journal:  Ecancermedicalscience       Date:  2016-11-08

Review 8.  Radiation Therapy in Keloids Treatment: History, Strategy, Effectiveness, and Complication.

Authors:  Jing Xu; Elan Yang; Nan-Ze Yu; Xiao Long
Journal:  Chin Med J (Engl)       Date:  2017-07-20       Impact factor: 2.628

Review 9.  Recent Understandings of Biology, Prophylaxis and Treatment Strategies for Hypertrophic Scars and Keloids.

Authors:  Ho Jun Lee; Yong Ju Jang
Journal:  Int J Mol Sci       Date:  2018-03-02       Impact factor: 5.923

10.  A hesitated approach: primary radiotherapy for keloids-a case series.

Authors:  Sezin Yuce Sari; Melek Tugce Yilmaz; Gozde Yazici; Hakan Uzun; Fazli Yagiz Yedekci; Gokhan Ozyigit
Journal:  Strahlenther Onkol       Date:  2021-01-04       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.